HAIFA, Israel--(BUSINESS WIRE)--March 6, 2006--Pluristem Life Systems, Inc. (OTC BB:PLRS), a biotechnology company dedicated to the commercialization of cell therapy products, today announced that the Company is changing its business strategy. Instead of working towards the goal of licensing out the use of its proprietary bioreactor-enabling technology, the company plans to develop cell therapy products that can be marketed on a for-sale basis. The company expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation (BMT).
